Related Experiment Videos
Primary heart disease in systemic sclerosis (scleroderma): advances in clinical and pathologic features,
Insights
Heart disease in Systemic Sclerosis with Cardiac Locus (SSCL) can be primary or secondary, involving various cardiac structures and leading to heart failure symptoms. Current treatments are symptomatic, highlighting the need for novel therapeutic strategies.
Area of Science:
- Cardiology
- Rheumatology
- Pathology
Background:
- Heart disease is a significant complication in Systemic Sclerosis with Cardiac Locus (SSCL).
- Cardiac involvement in SSCL can manifest as primary or secondary conditions.
- Understanding the spectrum of cardiac pathology in SSCL is crucial for patient management.
Purpose of the Study:
- To outline the primary and secondary cardiac manifestations in SSCL.
- To describe the clinical symptoms associated with SSCL-related heart disease.
- To explore potential pathogenetic mechanisms and current therapeutic limitations.
Main Methods:
- Review of existing literature on cardiac involvement in SSCL.
- Analysis of pathological findings including pericarditis, myocardial fibrosis, and coronary artery lesions.
- Correlation of clinical symptoms with cardiac pathology.
Main Results:
- Primary SSCL cardiac disease includes pericarditis, myocardial fibrosis, and cardiomyopathy.
- Symptoms encompass heart failure, chest pain, palpitations, syncope, and sudden death.
- Pathogenesis may involve cardiac Raynaud's phenomenon or small vessel disease.
Conclusions:
- SSCL presents diverse cardiac pathologies requiring comprehensive evaluation.
- Current therapeutic strategies for SSCL cardiac disease are primarily symptomatic.
- There is a critical need for the development of new, targeted therapies for SSCL-related heart conditions.
Abstract:
Heart disease in SSCL may be primary or secondary. Primary involvement includes pericarditis, myocardial fibrosis, and contraction band necrosis with congestive cardiomyopathy, conduction system fibrosis, intramural coronary artery lesions and, rarely, valvular disease. Symptoms include those of left and right ventricular failure, chest pain, palpitations, syncope, and sudden death. Pathogenesis may be related to functional Raynaud's phenomenon of the heart and/or structural small vessel disease. Therapy at present is symptomatic; however, new therapeutic approaches are warranted.